Related Experiment Video

Updated: Jan 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how?

Misako Nagasaka1, Husain Y Khan2, Faustine Luo1

  • 1University of California Irvine School of Medicine, Orange, CA, USA.

Translational Lung Cancer Research
|September 15, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
KRAS inhibitorseltanexornon-small cell lung cancer (NSCLC)nuclear exportselinexor

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.6K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

Related Experiment Videos

Last Updated: Jan 17, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.6K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

Articles linked to this work by shared authors, journal, and citation graph.

Evaluating taletrectinib in the treatment of patients with ROS1 fusion-positive non-small cell lung cancer.

Future oncology (London, England)·2026

Can We Extend Beyond 2 Years of Adjuvant ALK TKI Established by ALINA and ELEVATE in Resected Early Stage ALK+ NSCLC a Disease with High Predilection for CNS Metastasis with Novel Clinical Trial Designs?

Lung Cancer (Auckland, N.Z.)·2026

Genomic and Transcriptomic Landscapes of MEN1-Wild-Type Low-Grade Metastatic Pancreatic NETs Uncover Key Oncogenic Drivers and Targetable Pathways.

International journal of biological sciences·2026

Healing of Post-Operative Tracheal Disruption in a Patient with Thymic Carcinoma on Adjuvant Immunotherapy.

Lung Cancer (Auckland, N.Z.)·2026

XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma.

Cancer letters·2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

The Lancet. Oncology·2026

Synergistic effects and molecular mechanisms of pirfenidone combined with EGFR-TKIs in non-small cell lung cancer.

Translational lung cancer research·2026

Multimodal digital assessment of early recovery after chest tube omission in early-stage lung cancer patients undergoing wedge resection: a post hoc analysis of a prospective cohort.

Translational lung cancer research·2026

A structural dose-response relationship between lymph node yield and survival after anatomical segmentectomy for early-stage NSCLC: a SEER-based retrospective cohort study.

Translational lung cancer research·2026

Retrospective real-world associations between EGFR alterations and furmonertinib outcomes in advanced non-small cell lung cancer.

Translational lung cancer research·2026

Bioelectrical impedance-derived body composition and systemic therapy outcomes in non-small cell lung cancer.

Translational lung cancer research·2026

Regional disparities in lung cancer surgery and survival in South Korea: a nationwide population-based retrospective cohort study using linked cancer registry and national health insurance data.

Translational lung cancer research·2026

Redox-metabolic cascade NIR-II prodrug for synchronizing compensatory HSPs/P-gp feedback with mitophagy flux impairment against intrinsic thermotolerance.

International journal of pharmaceutics: X·2026

HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges.

Frontiers in cell and developmental biology·2026

Beyond vitamin D: integrating nuclear receptor signaling networks in periodontal health and disease.

Frontiers in physiology·2026

Cellular signaling meets bacterial infection: the integrative role of STAT3.

Frontiers in cellular and infection microbiology·2026

Kidney transplantation in multiple myeloma: patient selection, timing, and post-transplant challenges in the modern therapeutic era.

Clinical kidney journal·2026

A review of advances in research on mechanisms inhibiting kidney stone formation from a network pharmacology perspective.

Frontiers in pharmacology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us